Phen’X Technologies has sold a majority stake to Ciclad
The shareholders of Phen’X Technologies have completed a primary majority LBO with private equity fund Ciclad.
Founded in 2011, Phen’X Technologies is specialized in medical subcontracting of implants and instruments for dental, maxillofacial and orthopedic applications. With two production sites in France and Portugal, the company manufactures a wide range of components to support surgeons in dental implantology, facial remodeling and orthopedics. The firm also assists its clients in industrialization projects, from the realization of 3D plans and prototypes to the machining of mass-produced parts.
Ciclad is a long-standing, independent private equity investor supporting the growth of small and mid-sized companies in France and abroad. Established in 1988, Ciclad has invested alongside more than 180 executives and management teams. It is involved in buy-outs and capital strengthening, particularly complex transactions such as spin-offs and carveouts, in contexts of strong development – organic growth and build-up – and turnarounds.
Oaklins’ team in France acted as the exclusive financial advisor to the shareholders of Phen’X Technologies in this LBO.
Contacter l'équipe de la transaction
Transactions connexes
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
En apprendre plusGroupe JVS has completed an LBO with Capza and Bpifrance
The shareholders of Groupe JVS have completed an LBO with Capza and BpiFrance. Parquest sold their shares after partnering with the organization for three years. Groupe JVS’s management team will increase its ownership and remain as the majority shareholder of the group, alongside CAPZA and Bpifrance.
En apprendre plusCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
En apprendre plus